Novartis India Limited has submitted a regulatory filing to BSE Limited pursuant to Regulation 30 read with Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.
The disclosure intimates that company officials will be meeting with investors and analysts at the Nuvama - Emerging India CEO Forum investor conference. The meeting is scheduled for Monday, September 28, 2026, in Mumbai and will be conducted in-person. The meeting format will include both one-on-one (1 X 1) and/or group meetings.
The company explicitly states that no Unpublished Price Sensitive Information (UPSI) will be disclosed during these meetings. The filing notes that the schedule is subject to change due to exigencies on either side.
The document was digitally signed by Chandni Maru, Company Secretary and Compliance Officer (A60291), on September 23, 2026, at 17:09:21 IST.